Air Canada announced it will start non-stop seasonal flights between Montréal and Seville, Spain, beginning September 8, 2027. This new route is the only direct connection between North America and Seville, enhancing travel options for Canadians and international travelers to southern Spain. The service will operate up to four times weekly using the Airbus A321XLR, offering a premium travel experience. This expansion strengthens Air Canada's position as the largest carrier between Canada and Spain and supports year-round tourism growth in Montréal.
Air Canada's new seasonal Montréal-Seville route is announced as part of its expanding European network. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Oct 14, 2026 19:02 WIB: out of 134 priced US stocks, 94 rose and 33 fell. Notable movers include Nike Inc (NKE) at USD 35.72 with a 1-day change of +1.10% and a typical hold time of 155 days, Newegg Commerce Inc (NEGG) at USD 11.01 down 1.08%, and Home Depot Inc (HD) at USD 297.04 up 1.06% with strong buy order activity at 93%.
Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...
Air Canada will begin a new seasonal nonstop flight service between Montreal and Seville, Spain, starting September 8, 2027. This route is the only nonstop connection between North America and Seville, enhancing travel options for leisure and busines...
CodeWall Ltd. has emerged from stealth with $4 million in pre-seed funding to develop AI-powered autonomous attack agents that simulate real-world cyberattacks on enterprises. These agents start from outside the network with no insider access, contin...
Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...
Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...
